Vitamin D3 + K2: The Underrated Cognitive Aging Combination

Why vitamin D matters for the brain

Vitamin D isn't traditionally categorized as a brain supplement, but the receptor biology and epidemiology tell a different story. Vitamin D receptors (VDR) are expressed throughout the brain, with particular density in the substantia nigra, hippocampus, and hypothalamus. Vitamin D metabolism enzymes (1-alpha-hydroxylase) are present in brain tissue.

Functionally, vitamin D in the brain:

• Modulates NGF, GDNF, and other neurotrophic factors
• Regulates calcium homeostasis in neurons
• Has anti-inflammatory effects via microglial modulation
• Influences dopamine synthesis and function (relevant to Parkinson's risk)
• Supports amyloid-β clearance in preclinical models

Serum 25-hydroxyvitamin D — the standard clinical measure — reflects vitamin D status. Deficiency (below 50 nmol/L or 20 ng/mL) is extremely common: roughly 40% of US adults are deficient by this cutoff, and the proportion is higher in older adults, Black and Hispanic populations, and northern latitudes.^[1]

The Littlejohns dementia data

Littlejohns 2014 analyzed data from the Cardiovascular Health Study — 1,658 adults over age 65 followed for a mean of 5.6 years. Baseline vitamin D status was measured; incident all-cause dementia and Alzheimer's disease were tracked.^[2]

Results (compared to those with 25(OH)D ≥50 nmol/L):

• Deficient (25-49 nmol/L): 53% increased risk of all-cause dementia
• Severely deficient (<25 nmol/L): 122% increased risk of all-cause dementia
• Similar dose-response pattern for Alzheimer's disease specifically

This is observational data — it doesn't prove that raising vitamin D prevents dementia. Confounding by underlying disease, lifestyle factors, and other factors is possible. But the effect size is large, the dose-response pattern is clean, and the mechanistic story is well-supported.

Balion 2012 conducted a systematic review of 37 studies of vitamin D and cognitive function, finding significant associations between low vitamin D status and cognitive impairment across most included studies.^[3]

Randomized supplementation trials for cognitive endpoints have been more mixed — VITAL-DEP (Kang 2019) tested 2,000 IU D3 in 25,000+ adults with cognitive complaints; the primary depression endpoint was negative.^[4] But most of these RCTs enrolled adults with relatively adequate baseline D status, where the marginal benefit of additional D would be small by design.

Why K2 belongs in the same bottle

Vitamin D3 supplementation increases calcium absorption from the gut. Where that calcium goes matters enormously:

• Bone: desired destination — mineralizes bone matrix, prevents osteoporosis
• Blood vessels and soft tissue: undesired destination — contributes to arterial calcification, kidney stones, and soft-tissue calcification

Vitamin K2 (specifically menaquinone-4 and menaquinone-7 forms) activates two proteins that direct calcium traffic:

• Osteocalcin: once K2-activated, binds calcium to bone matrix
• Matrix Gla protein (MGP): once K2-activated, prevents calcium deposition in arteries and soft tissue

Without adequate K2, both proteins remain inactive. Calcium mobilized by high D3 supplementation ends up in less desirable locations. Beulens 2013 documented associations between low K2 intake and increased coronary artery calcification.^[5]

K2 deficiency is quite common in Western diets (K2 comes from fermented foods — natto is the highest source — plus some animal fats and organ meats). The therapeutic case for combining D3 with K2 is well-supported by both mechanism and cardiovascular outcome data.

The forms and doses that matter

Most consumer D3+K2 products use MK-7 for the K2 component because of its once-daily dosing profile and long half-life. Fatty foods improve absorption of both — both are fat-soluble vitamins.

Testing matters more than dosing formulas. Serum 25(OH)D varies enormously between individuals at the same supplement dose based on body weight, skin pigmentation, sun exposure, and genetics. Target range for cognitive benefit: 75-125 nmol/L (30-50 ng/mL). Test annually if supplementing. Adjust dose based on results.

Dosing

Toxicity thresholds: D3 toxicity from supplementation is rare below 10,000 IU/day sustained for months. Typical supplement doses (2,000-5,000 IU) are safely below toxicity threshold with virtually no risk in adults with normal kidney function.

K2 has an even wider safety margin — no established upper limit for K2 in the US, with intake doses up to 45 mg/day (MK-4) tested for osteoporosis with no toxicity signals.

Who benefits, who should skip

D3 + K2 is a strong fit for:

• Adults 40+ living at latitudes above 35° (roughly northern half of US, all of Canada, most of Europe) where sun-derived vitamin D synthesis is inadequate for much of the year
• Adults with dark skin pigmentation living anywhere with less sun
• Anyone who works indoors, uses sunscreen consistently, or has limited outdoor exposure
• Older adults — skin vitamin D synthesis declines substantially with age
• Obese individuals — vitamin D distributes into adipose tissue, requiring higher doses to raise serum levels
• Anyone with a documented 25(OH)D under 75 nmol/L

Coordinate with your physician if:

• You take warfarin — K2 affects vitamin K-dependent clotting factors and can require warfarin dose adjustment. K2 doesn't preclude warfarin use, but the dosing needs to be coordinated and stable.
• You have hypercalcemia or a history of it — additional vitamin D can worsen the problem
• You have sarcoidosis or other granulomatous conditions — abnormal vitamin D metabolism can cause hypercalcemia at moderate supplement doses
• You have kidney disease — vitamin D metabolism is impaired; specialist dosing needed
• You take digoxin — hypercalcemia from D3 excess potentiates digoxin toxicity

Why this belongs in a brain supplement stack

Most brain-focused supplement stacks skip vitamin D3 and K2 because they don't feel "cognitive" enough. This is a mistake.

The math: vitamin D deficiency is common (~40% of US adults), the association with dementia is unusually strong for a nutritional factor (dose-response of 53% to 122% increased risk depending on severity), correction is inexpensive ($10-20/month for D3+K2), and the safety margin is wide.

Compared to the marginal effects of most specialty nootropics on well-nourished adults, correcting a documented vitamin D deficiency probably produces larger cognitive and general health benefits per dollar spent. It's just less exciting to talk about than the latest peptide or nootropic.

Practical recommendation: get a 25(OH)D test at your next physical (usually included in standard bloodwork on request). If under 75 nmol/L (30 ng/mL), begin D3+K2 supplementation and retest in 3-4 months. Adjust dose to reach and maintain 75-125 nmol/L. This one intervention often produces more measurable benefit than three or four specialty cognitive supplements combined.